Netherlands Brain Foundation Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2000
NCT00432081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Netherlands Brain Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Craniocerebral Trauma (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6